Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jan;20(1):17-21.
doi: 10.1080/14787210.2021.1939683. Epub 2021 Jun 15.

NSAIDs/nitazoxanide/azithromycin repurposed for COVID-19: potential mitigation of the cytokine storm interleukin-6 amplifier via immunomodulatory effects

Mina T Kelleni  1
Affiliations

NSAIDs/nitazoxanide/azithromycin repurposed for COVID-19: potential mitigation of the cytokine storm interleukin-6 amplifier via immunomodulatory effects

Mina T Kelleni. Expert Rev Anti Infect Ther. 2022 Jan.

Abstract

Introduction: Mediators of immunity and inflammation are playing a crucial role in COVID-19 pathogenesis and complications as demonstrated by several genetic and clinical studies. Thus, repurposing of drugs that possess anti-inflammatory and/or immune-modulatory effects for COVID-19 is considered a rational approach.

Areas covered: We analyze selected studies that correlated COVID-19 with dysregulated interferon and inflammatory responses while reflecting on our academic and real-life experience using non-steroidal anti-inflammatory drugs, nitazoxanide and azithromycin for management of COVID-19. Moreover, we interpret the results that suggested a potential survival benefit of low-dose aspirin and colchicine when used for COVID-19.

Expert opinion: Nitazoxanide/azithromycin combination has been first hypothesized by the author and practiced by him and several researchers to benefit COVID-19 patients due to a potential ability to augment the natural interferon response as well as their positive immunomodulatory effects on several cytokines. Furthermore, NSAIDs, that are unfortunately currently at best of second choice after paracetamol, have been early postulated and clinically practiced by the author to prevent or ameliorate COVID-19 complications and mortality due to their anti-inflammatory and immunomodulatory properties. Finally, we repeat our previous call to adopt our observational study that used these drugs in sufficiently powered double blind randomized clinical trials.

Keywords: COVID-19; Diclofenac; IL-6 amplifier; Interferons; NF-kB; NSAIDS; azithromycin; ibuprofen; monocytic immunological dysrhythmia; nitazoxanide.

PubMed Disclaimer

Figures

None
Graphical abstract
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Dhama K, Patel SK, Pathak M, et al. An update on SARS-CoV-2/COVID-19 with particular reference to its clinical pathology, pathogenesis, immunopathology and mitigation strategies. Travel Med Infect Dis. 20202020/09/01/;37:101755. - PMC - PubMed
    1. Prompetchara E, Ketloy C, Palaga T.. Immune responses in COVID-19 and potential vaccines: lessons learned from SARS and MERS epidemic. Asian Pac J Allergy Immunol. 2020. March;38(1):1–9. - PubMed
    1. Attia YA, El-Saadony MT, Swelum AA, et al. COVID-19: pathogenesis, advances in treatment and vaccine development and environmental impact—an updated review. Environ Sci Pollut Res. 2021;28(18):22241–22264. . 2021/ 03/18 - PMC - PubMed
    1. *Pairo-Castineira E, Clohisey S, Klaric L, et al. Genetic mechanisms of critical illness in Covid-19. Nature. 2020;591(7848):92–98. . 2020/12/11 - PubMed
    1. Karaderi T, Bareke H, Kunter I, et al. Host Genetics at the Intersection of Autoimmunity and COVID-19: a Potential Key for Heterogeneous COVID-19 Severity [Perspective]. Front Immunol. 2020. December;22(11):3314. - PMC - PubMed

MeSH terms